China SASAC approves North China Pharma shareholder's stake sale to DSM
North China Pharmaceutical Co Ltd (SHA 600812) said the State-owned Assets Supervision and Administration Commission (SASAC) has granted approval for its largest shareholder, North China Pharmaceutical Group, to sell a 7.64 pct stake in the company to Dutch chemicals group DSM NV.
North China Pharmaceutical said in a statement to the Shanghai Stock Exchange that its largest shareholder will sell 58 mln state-owned shares at 3.55 yuan each for a total of 206.6 mln.
It said the proceeds from the sale will be used to repay part of the amount it is owed by North China Pharmaceutical Group, which totaled 1.2 bln yuan as of the end of June.
The SASAC has granted approval to North China Pharmaceutical Group to sell an additional 400 state-owned shares in the company at 2.46 yuan each to settle the remaining 1 bln debt.
The listed company said the two deals remain subject to shareholder approval. North China Pharmaceutical said more than 50 pct of its public shareholders will vote on the transactions via the Internet.
(1 usd = 8.3 yuan)
国资委批准华北制药以股抵债方案
华北制药股份有限公司(SHA 600812)发布公告称, 国资委已批准其控股股东华药集团将持有华北制药的5,800万股转让给荷兰ROYAL DSM N. V.公司, 每股转让价格为3.55元, 转让收入20,660万元全部用于偿还华药集团及其关联单位对华北制药欠下的债务。
公告指出, 国资委还批准华药集团将持有华北制药的4.07亿股国家股每股作价2.46元, 总计作价10亿元转让给华北制药, 以抵偿其所欠的等额债务。
公告又指, 根据有关规定, 华北制药2004年第二次临时股东大会拟讨论的“以股抵债”事项
, 除须经全体股东大会表决通过外, 还必须经参加表决的社会公众股股东所持表决权的半数以上通过。
